Cantor Fitzgerald raised the firm’s price target on Korro Bio (KRRO) to $22 from $21 and keeps an Overweight rating on the shares. The firm updated its model after Korro Bio reiterated guidance for an IND/CTA-type regulatory filing for KRRO-121 in hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy in 2H26, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio upgraded to Outperform from Market Perform at Raymond James
- Korro Bio Announces Oversubscribed $85M PIPE Financing
- Korro Bio prices 4.5M shares at $11.11 in private placement
- Korro Bio upgraded to Buy from Hold at Clear Street
- Korro Bio upgraded to Outperform from Market Perform at William Blair